Scientific deep-dive
Seizures When You Already Have Epilepsy
A careful study of epilepsy and type 2 diabetes found fewer seizures with GLP-1s, and 60% lower mortality. No glucose-lowering drug does that, and the implausible number is the informative one.
If you already have epilepsy and are offered a GLP-1 for your diabetes, the question is whether it affects your seizures. A study of 8,688 matched pairs reports fewer seizures, with a hazard ratio of 0.82.[1] It also reports 60% lower mortality from the same comparison, and that second number is the reason to be careful with the first.
What was done
Using electronic health records from a large multinational network, researchers identified adults with at least three epilepsy or recurrent-seizure diagnoses who also had type 2 diabetes. Those starting a GLP-1 were matched one-to-one against those starting a different glucose-lowering drug (an SGLT2 inhibitor, a DPP-4 inhibitor, a sulfonylurea or insulin), using propensity scores built from 82 covariates. That produced 8,688 matched pairs.
That is a serious piece of methodology. Eighty-two covariates is thorough, the sample is large, and the follow-up runs well over a year in both arms.
| Outcome | Hazard ratio (95% CI) | Risk difference |
|---|---|---|
| Seizure recurrence | 0.82 (0.78–0.86) | −2.1% |
| Status epilepticus | 0.75 (0.66–0.85) | −0.7% |
| Hospitalization | 0.35 (0.29–0.43) | −2.6% |
| All-cause mortality | 0.40 (0.34–0.47) | −4.8% |
| ICU admission | 0.82 (0.69–0.96) | −0.3% |
Why the mortality figure is the tell
The mechanism is well understood and has a name, and we set it out at length in when a hazard ratio is too good, where the same shape appears in a study of psoriasis patients. In short: GLP-1 medicines go to people who are healthier, better insured and more engaged with their care, while the sickest and frailest disproportionately end up on insulin, which sits in the comparison group.
Propensity matching corrects for what is written in the record: diagnoses, medications, laboratory values, demographics. It cannot correct for what is not recorded. General frailty, the thing that best predicts who dies within two years, is largely not recorded. Eighty-two covariates matched on paper can still leave two groups of visibly different people.
When the effect on death exceeds what randomized trials found, the extra is measuring who got the prescription.
What that does to the finding you came for
The study is about seizures, and its seizure result is modest and biologically plausible: a hazard ratio of 0.82, an absolute risk difference of 2.1 percentage points. Taken alone, it would be a finding worth taking seriously.
It cannot be taken alone. It comes from the same comparison between the same two groups whose mortality difference demonstrates those groups were not alike. If unmeasured health explains most of a 60% mortality gap, it is also available to explain a 2.1-point seizure gap. Healthier people with better-controlled diabetes have fewer seizures for reasons that have nothing to do with which drug they were given.
The general point is that an implausible result does not sit quietly in its own row. It is evidence about the whole comparison, and it discredits the plausible findings beside it.
A separate question is whether these drugs affect the chance of developing epilepsy in the first place, rather than seizure recurrence in people who already have it. That is examined in GLP-1s and epilepsy risk, and the pattern inside those numbers points the same way.
One sentence we cannot reconcile
To the authors' credit
They describe their own findings as hypothesis-generating and say they warrant confirmation in prospective studies before being translated into practice. That is the correct characterization, and it is not a formality: plenty of papers with weaker designs claim more.
What this analysis does establish is that the question is worth asking. There are mechanistic reasons to wonder whether these drugs affect seizure threshold, and a signal in 8,688 matched pairs is a reasonable basis for designing a trial. It is not a basis for prescribing.
Frequently Asked Questions
References
- 1.AbuAlrob MA, Hussein A, Abdellatif R, et al. Seizure recurrence after GLP-1 receptor agonist initiation in adults with epilepsy Epilepsia. 2026. PMID: 41251033.
Compare the sellers
Related research
A Biomarker Is Not an Outcome
Sixteen cardiovascular risk markers were measured in SURMOUNT-1 at 72 weeks, and most improved substantially. Cardiology has learned twice, expensively, why that is not the same as preventing events.
8 min read
A Weight Drug for Having Too Little Fat
Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.
6 min read
The Drugs That Are Not Here Yet
Four investigational molecules have published human results. The most striking figure among them, 8% of body weight in four weeks, comes from the earliest and smallest study of the four.
8 min read
Five Hundred Calories at One Lunch
Researchers weighed what 114 people ate at a free-access lunch. Three weeks into tirzepatide they ate 524.6 fewer calories, without any increase in conscious dietary restraint.
6 min read
Uric Acid and Two Answers
Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect 72.7% explained by weight loss; the other found it independent of weight loss.
7 min read
What These Hormones Do Without a Pancreas
To isolate what the gut hormones do outside the pancreas, researchers studied twelve people who no longer have one, and blocked the receptors. The one clear result was about bone.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo + membership
Get started →Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →